High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib

International Journal of Hematology

Volumn 98, Issue 6, 2013, Pages 694-701

  Kamimura, Tomohiko ^a   Miyamoto, Toshihiro ^b   Yokota, Noriko ^a   Aoki, Takatoshi ^a   Ito, Yoshikiyo ^a   Akashi, Koichi ^b  

^a HARASANSHIN HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Bortezomib; Injection; Multiple myeloma; Site reaction; Subcutaneously

Indexed keywords

BORTEZOMIB;

ABDOMEN; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; ERYTHEMA; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHLEBITIS; THIGH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BORONIC ACIDS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PYRAZINES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84891163036     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1469-7     Document Type: Article

References (19)

1. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:303-9.
2. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematology Am Soc Hematol Educ Program. 2011;2011:191-6.
3. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947-59.
4. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311-9.
5. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895-903.
6. Lonial S. Is subcutaneous bortezomib ready for prime time? Curr Hematol Malig Rep. 2011;6:73-4.
7. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93:1908-11.
8. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-40.
9. Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97:1925-8.
10. Mader I, Fürst-Weger P, Made R, Nogler-Semenitz E, Wassertheurer S. Extravasation of cytotoxic agents: compendium for prevention and treatment. New York: Springer; 2010. p. 127-9.
11. Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, Feng H, Girgis S, Cakana A, van de Velde H, Deraedt W, Facon T. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51:823-9.
12. Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, Ito Y, Akashi K. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eur J Haematol. 2013;90:157-61.
13. Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011;31:2297-302.
14. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R, Stewart AK. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115:3416-7.
15. Health NCIatNIo: common terminology criteria for adverse events (CTCAE) version 4.0. http://www.eortc.be/services/doc/ctc/CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf.
16. Obeid KM, Ferrara R, Sharma M. Cutaneous lesion induced by a subcutaneous administration of bortezomib. Clin Lymphoma Myeloma Leuk. 2012;12:284-6.
17. Kamimura T, Miyamoto T, Takashima S, Yokota N, Chong Y, Ito Y, Akashi K. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma. Int J Hematol. 2012;96:525-7.
18. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-24.
19. Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther. 2003;1:38-48.